Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

Ayisha Sharma

News Reporter

Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments with an upfront payment of $36 million. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Ahead of FDA decision, Alnylam faces the big question: Can it make money?

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exit

Sixteen-year-old dies after receiving Sarepta’s Duchenne gene therapy

Roche inks $1B+ biobucks deal with UK biotech for new an­ti­body can­cer tar­gets

News Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Roche inks $1B+ biobucks deal with UK biotech for new antibody cancer targets